The next generation of novel therapies for the management of relapsed multiple myeloma

Wilson I. Gonsalves, Paolo Milani, Daniel Derudas, Francis K. Buadi

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

The advent of various novel therapies such as immunomodulators and proteasome inhibitors has transformed the treatment paradigm for patients with multiple myeloma (MM). As a result, the overall survival has improved dramatically over the last decade. Despite these advances, MM remains mostly incurable and most patients experience disease relapse after enjoying a period of disease control or remission. Fortunately, the scientific community continues to make strides in developing 'next-generation' therapies for the management of patients with relapsed MM. This review will summarize the efficacy of some of the newest therapeutic agents available for the treatment of patients with relapsed MM after their upfront treatment with the original novel agents such as thalidomide, lenalidomide and bortezomib.

Original languageEnglish (US)
Pages (from-to)63-75
Number of pages13
JournalFuture Oncology
Volume13
Issue number1
DOIs
StatePublished - Jan 2017

Keywords

  • multiple myeloma
  • novel agents
  • relapse

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'The next generation of novel therapies for the management of relapsed multiple myeloma'. Together they form a unique fingerprint.

  • Cite this